Monoclonal antibody JST-010 + Placebo
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults
Conditions
Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults
Trial Timeline
May 16, 2025 → Oct 1, 2027
NCT ID
NCT06943378About Monoclonal antibody JST-010 + Placebo
Monoclonal antibody JST-010 + Placebo is a phase 1 stage product being developed by Evotec for Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06943378. Target conditions include Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults.
What happened to similar drugs?
0 of 4 similar drugs in Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults were approved
Approved (0) Terminated (0) Active (4)
🔄Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDFGilead SciencesPhase 3
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06943378 | Phase 1 | Recruiting |
Competing Products
7 competing products in Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDF | Gilead Sciences | Phase 3 | 44 |
| Lenacapavir Tablet + Lenacapavir Injection + Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Gilead Sciences | Phase 2 | 39 |
| Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only) | Gilead Sciences | Phase 3 | 44 |
| Lenacapavir Injection + Lenacapavir Tablet | Gilead Sciences | Phase 3 | 47 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 39 |
| F/TAF + F/TDF + F/TAF Placebo + F/TDF Placebo | Gilead Sciences | Phase 3 | 44 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 39 |